Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billionKelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.{}

Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.https://www.cnbc.com/2026/04/20/eli-lilly-to-acquire-cancer-drug-maker-kelonia.html